Okupe Oluyemi sold $355K of HIMS

A US federal judge ruled the FTC's lawsuit against Hims & Hers, alleging privacy and consumer protection violations, will likely proceed to trial. The case centers on the telehealth company's practices.

Eli Lilly (LLY) reported Q3 2026 revenue of $24.4B, up 39% YoY, beating estimates. It raised full-year revenue guidance to $91B-$92B. Mounjaro and Zepbound sales surged 65% and 49%, respectively. Novo Nordisk (NVO) and Viking Therapeutics (VKTX) saw minor stock movements.

HIMS stock rose 5% after HHS temporarily cleared the compounding of six peptides. The company faces an FTC lawsuit and margin pressures. Retail sentiment improved, with some users noting anticipation for earnings. HIMS stock is down 8% year-to-date. According to StockTwits, the clearance was seen as a positive development.

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

Hims & Hers Inc. (HIMS) shares rose after Health Secretary Robert F. Kennedy Jr. allowed sales of certain unapproved peptides without FDA approval. The Department of Health and Human Services stated it would not take legal action against companies selling these peptides.

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.